Janus Kinase Signaling Pathway and Its Role in COVID-19 Inflammatory, Vascular, and Thrombotic Manifestations.
Jonathan D RavidOrly LeivaVipul C ChitaliaPublished in: Cells (2022)
Acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection continues to be a worldwide public health crisis. Among the several severe manifestations of this disease, thrombotic processes drive the catastrophic organ failure and mortality in these patients. In addition to a well-established cytokine storm associated with the disease, perturbations in platelets, endothelial cells, and the coagulation system are key in triggering systemic coagulopathy, involving both the macro- and microvasculatures of different organs. Of the several mechanisms that might contribute to dysregulation of these cells following SARS-CoV-2 infection, the current review focuses on the role of activated Janus kinase (JAK) signaling in augmenting thrombotic processes and organ dysfunction. The review concludes with presenting the current understanding and emerging controversies concerning the potential therapeutic applications of JAK inhibitors for ameliorating the inflammation-thrombosis phenotype in COVID-19 patients.
Keyphrases
- respiratory syndrome coronavirus
- sars cov
- public health
- coronavirus disease
- oxidative stress
- induced apoptosis
- signaling pathway
- endothelial cells
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- drug induced
- liver failure
- prognostic factors
- protein kinase
- pulmonary embolism
- tyrosine kinase
- peritoneal dialysis
- risk factors
- epithelial mesenchymal transition
- pi k akt
- cardiovascular events
- case report
- respiratory failure
- intensive care unit